Latest marketing authorisations and orphan drug designations
Marketing authorisations and medicinal products designations
Detailed information on European orphan medicinal products designation applications is available on theEMA website. A full list of designated and authorised orphan medicinal products in Europe available at:ec.europa.eu.
Learn more about the Orphan designation process in Europe
Recent orphan drug designations
February 2014
Treatment of Farber disease
Recombinant human acid ceramidase
Prevention of congenital cytomegalovirus infection following primary cytomegalovirus infection
Mixture of recombinant human IgG1 monoclonal antibodies against human cytomegalovirus envelope glycoproteins
Treatment of epidermolysis bullosa
Diacerein
Diagnosis of gastro-entero-pancreatic neuroendocrine tumours
Gallium [Ga-68]-N-[(4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-Lcysteinyl-L-threonine-cyclic(27)disulfide
Prevention of delayed graft function after solid organ transplantation
Eculizumab
Treatment of cystic fibrosis
11-(4-Dimethylamino-3-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecane-13,15-dione
Treatment of cystic fibrosis
Cysteamine
Treatment of Duchenne muscular dystrophy
Asp-Arg-Val-Tyr-Ile-His-Pro
Treatment of Rett síndrome
3-Chloro-4-fluorophenyl-[4-fluoro-4-{[(5-methylpyrimidin-2-ylmethyl)amino]methyl}piperidin-1-yl]methanone
Treatment of polycythaemia vera
Ruxolitinib
Treatment of adrenoleukodystrophy
Pioglitazone
Diagnosis of gastro-entero-pancreatic neuroendocrine tumours
68Ga-2,2'-(7-(4-((S)-1-((4S,7S,10S,13R,16S,19R)-4-((R)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-ylcarbamoyl)-10-(4-aminobutyl)-16-(4-((S)-2,6-dioxohexahydropyrimidine-4-carboxamido)benzyl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-13-(4-ureidobenzyl)-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-19-ylamino)-3-(4-chlorophenyl)-1-oxopropan-2-ylamino)-1-carboxy-4-oxobutyl)-1,4,7-triazonane-1,4-diyl)diacetic acid
Treatment of glioma
Autologous dendritic cells pulsed with tumour antigen-derived synthetic peptides (MAGE-1, HER-2, AIM-2, TRP-2, gp-100, and interleukin-13 receptor alpha)
Treatment of optic neuritis
N-({Carbamoylmethyl-[3-(2-oxo-pyrrolidin-1-yl)-propyl]-carbamoyl}-methyl)-2-[2-(2-fluoro-phenyl)-ethylamino]-N-isobutyl-acetamide
Treatment of familial chylomicronemia syndrome
Phosphorothioate oligonucleotide targeted to apolipoprotein CIII
January 2014
Treatment of malignant mesothelioma
Amatuximab
Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma
Inecalcitol
Treatment of aneurysmal subarachnoid haemorrhage
Sodium nitrite
Treatment of hepatitis delta virus infection
Lonafarnib
Treatment of dystrophic myotonia
(6aS)-1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4Hdibenzo[de,g]quinoline-2,9-diol
Treatment of adenovirus infection in allogeneic haematopoietic stem-cell transplant recipients
Adenovirus-specific T-cells derived from allogeneic donor leukocytes, expanded ex vivo
Treatment of primary sclerosing cholangitis
Obeticholic acid
Treatment of malignant mesothelioma
Autologous dendritic cells pulsed with allogeneic tumour cell lysate
Treatment of acute myeloid leukaemia
(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl) amino) methyl)tetrahydrofuran-3,4-diol
Treatment of acute lymphoblastic leukaemia
(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1Hbenzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol
Treatment of epidermolysis bullosa
Allantoin
Prevention of graft-versus-host disease
Allogeneic bone-marrow derived ex-vivo expanded multipotent adult progenitor cells
Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma
N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino) phenyl)acrylamide benzenesulfonic acid salt
December 2013
Treatment of cystic fibrosis
Nitric oxide
Treatment of hypoparathyroidism
Recombinant human parathyroid hormone
Treatment of glioma
Allogeneic and autologous haptenised and irradiated cells and cell lysates derived from glioma
Treatment of follicular lymphoma
Ibrutinib
Prevention of necrotizing enterocolitis
Lactobacillus acidophilus and Bifidobacterium bifidum
Treatment of Alagille síndrome
(4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane chloride
Treatment of primary biliary cirrosis
(4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane chloride
Treatment of progressive familial intrahepatic cholestasis
(4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane chloride
Treatment of primary sclerosing colangitis
(4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane chloride
Prevention of arteriovenous access dysfunction in haemodialysis patients
Recombinant human type I pancreatic elastase
Treatment of Dravet syndrome
Fenfluramine hydrochloride
Treatment of dengue
Poly[2-[(4-{[1-carboxy-2-(hexadecylcarbamoyl)ethyl]sulfanyl}-2,3-bis({2-[((2S)-2-(2-{[(2R)-2-carbamoyl-(2-{[(2S)-1-ethoxy-3-(3-hydroxy-4oxo-1,4-dihydropyridin-1-yl)-1-oxopropan-2-yl]carbamoyl}ethyl]sulfanyl}-3-{[(2S)-1-ethoxy-3-(3-hydroxy-4-oxo-1,4-dihydropyridin-1-yl)-1-oxopropan-2-yl]carbamoyl}propanamido)-3-(3-hydroxy-4-oxo-1,4-dihydropyridin-1-yl)propanoyl Ethyl ester) )-methoxy]acetyl}oxy)butyl)sulfanyl]-3-(hexadecylcarbamoyl)propanoic acid]-poly(ethylene glycol)-ester]
Treatment of haemophilia A
Humanised monoclonal modified IgG4 antibody with bispecific structure targeting factors IX, IXa, X and Xa
November 2013
Treatment of glioma
Autologous ex-vivo-expanded leucocytes treated with 5-aza-2’-deoxycytidine
Treatment of mucopolysaccharidosis type II (Hunter's syndrome)
Recombinant human insulin receptor monoclonal antibody-fusediduronate 2-sulfatase
Treatment of follicular thyroid cancer
Sorafenib tosylate
Treatment of papillary thyroid cancer
Sorafenib tosylate
Prevention of graft-versus-host disease
Defibrotide
Treatment of hepatocellular carcinoma
Tivantinib
Treatment of diffuse large B-cell lymphoma
Ibrutinib
Prevention of arteriovenous access dysfunction in patients undergoing surgical creation of an arteriovenous access for haemodialysis
Sirolimus
Treatment of eosinophilic oesophagitis
Human monoclonal antibody against human interleukin 13
Treatment of spinal cord injury
Synthetic 12 amino acids peptide designed after subcommissural organ spondin
Treatment of ovarian cancer
Trebananib
Treatment of Stargardt’s disease
Soraprazan
October 2013
Treatment of congenital factor VII deficiency
Recombinant fusion protein linking coagulation factor VIIa with Albumin
Treatment of myotonic disorders
Mexiletine hydrochloride
Treatment of plasma cell myeloma
Recombinant human monoclonal IgM antibody targeting glucose-regulated protein 78
Treatment of sarcoidosis
L-Pyr-L-Glu-L-Gln-L-Leu-L-Glu-L-Arg-L-Ala-L-Leu-L-Asn-LSer-L-Ser
Treatment of complex regional pain syndrome
Zoledronic acid
Treatment of Allan-Herndon-Dudley syndrome
3,5-diiodothyropropionic acid
Treatment of Duchenne muscular dystrophy
Naproxcinod
Treatment of cystic fibrosis
Antisense oligonucleotide targeting the F508delta mutation of CFTR
Treatment of Wiskott-Aldrich-syndrome
Autologous CD34+ cells transduced with a lentiviral vector containing the human Wiskott-Aldrich syndrome gene
July & August 2013
Treatment of pulmonary alveolar proteinosis
Granulocyte macrophage colony stimulating factor
Autologous bone marrow-derived mesenchymal stromal cells secreting neurotrophic factors
Autologous bone marrow-derived mesenchymal stromal cells secreting neurotrophic factors
Prevention of ischaemia/reperfusion injury associated with solid organ transplantation
Human hemin
Treatment of B-lymphoblastic leukaemia/lymphoma
Moxetumomab pasudotox
Treatment of malignant thymomas
Belinostat
Treatment of pancreatic cancer
(1-methyl-2-nitro-1H-imidazole-5-yl) methyl N,N’-bis(2-bromoethyl) diamidophosphate
Treatment of plasma cell myeloma
Daratumumab
Treatment of ovarian cancer
Fosbretabulin tromethamine
Treatment of amyotrophic lateral sclerosis
Allogeneic motor neuron progenitor cells derived from human embryonic stem cells
Prevention of hepatitis B re-infection following liver transplantation
Recombinant human monoclonal antibody against hepatitis B Virus
Treatment of follicular lymphoma
(S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
Treatment of ataxia telangiectasia
Dexamethasone sodium phosphate encapsulated in human autologous erythrocytes
Treatment of carbamoylphosphate synthase-1 deficiency
Heterologous human adult liver-derived progenitor cells
Treatment of citrullinaemia type 1
Heterologous human adult liver-derived progenitor cells
Treatment of argininosuccinic aciduria
Heterologous human adult liver-derived progenitor cells
Treatment of hyperargininaemia
Heterologous human adult liver-derived progenitor cells
Treatment of N-acetylglutamate synthetase (NAGS) deficiency
Heterologous human adult liver-derived progenitor cells
Treatment of citrullinaemia type 2
Heterologous human adult liver-derived progenitor cells
Treatment of ornithine translocase deficiency (hyperornithinaemia-hyperammonaemia homocitrullinuria (HHH) syndrome)
Heterologous human adult liver-derived progenitor cells
Treatment of limbal stem cell deficiency
Ex-vivo expanded autologous human corneal epithelium containing stem cells
Treatment of osteosarcoma
Lipid-complexed cisplatin
Treatment of acromegaly
Octreotide acetate (oral use)
Treatment of nodal marginal zone lymphoma
Idelalisib
Treatment of chronic lymphocytic leukaemia/small lymphocytic lymphoma
Idelalisib
Treatment of acute myeloid leukaemia
Trans-N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine bis-hydrochloride
Treatment of autosomal dominant polycystic kidney disease
Tolvaptan
Treatment of nontraumatic osteonecrosis
Human allogeneic bone marrow derived osteoblastic-like cells
Treatment of pancreatic cancer
Chimeric monoclonal antibody against claudin-18 splice variant 2
Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis
Pegylated recombinant anti-Pseudomonas aeruginosa PcrV Fab′antibody
Treatment of growth hormone deficiency
Recombinant human growth hormone modified by fusion with two hydrophilic polypeptide chains
Treatment of Behçets' disease
Apremilast
Treatment of eosinophilic oesophagitis
Budesonide
Treatment of mastocytosis
Cladribine
Treatment of congenital sucrase-isomaltase deficiency
Sacrosidase
Treatment of sickle cell disease
(1R,3R,4R,5S)-3-O-[2-O-benzoyl-3-O-(sodium(2S)-3-cyclohexyl-propanoate-2-yl)-β-D-galactopyranosyl]-4-O-(α-L-fucopyranosyl)-5-orothylamido-cyclohexane-1-carboxylic acid ethyl-2-amidyl-ethyloxy-2-acetyl-(8-amino-1,3,6-naphthalene-tris sodium sulfonate) amide
Treatment of neuromyelitis optica
Eculizumab
Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)
Idelalisib
Treatment of splenic marginal zone lymphoma
Idelalisib
June 2013
Treatment of cystic fibrosis
4,6,4’–trimethylangelicin
Treatment of 5q spinal muscular atrophy
5-[1-(2,6-dichlorobenzyl)piperidin-4-ylmethoxy]quinazoline-2,4-diamine dihydrochloride
Treatment of amyotrophic lateral sclerosis
Sodium chlorite
Treatment of retinitis pigmentosa
Expanded human allogeneic neural retinal progenitor cells extracted from neural retina
Treatment of pachyonychia congenital
Synthetic double-stranded siRNA oligonucleotide directed against the keratin 6a N171K mutation
Treatment of retinitis pigmentosa
Adenovirus associated viral vector serotype 5 containing the human pde6β gene
Treatment of acute liver failure
Immortalised human C3A hepatoblastoma cells
Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome)
Recombinant human alpha-N-acetylglucosaminidase
Treatment of soft tissue sarcoma
Genetically modified serotype 5/3 adenovirus coding for granulocyte-macrophage colony-stimulating factor
Treatment of retinitis pigmentosa
Unoprostone isopropyl
Treatment of non-dystrophic myotonia
Mexiletine hydrochloride
Treatment of B-cell acute lymphoblastic leukaemia
Inotuzumab ozogamicin
Treatment of adrenocortical carcinoma
N-[2,6-bis(1-methylethyl)phenyl]-N’-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt
Treatment of graft-versus-host disease
Allogeneic bone marrow derived mesenchymal cells expanded ex vivo in synthetic media
Treatment of transglutaminase-1-deficient autosomal recessive congenital ichthyosis
Recombinant human transglutaminase 1 encapsulated into liposomes
Treatment of cystic fibrosis
Recombinant human CXCL8 mutant
Treatment of malignant mesothelioma
N-methyl-4-({4-[({3-methyl(methylsulfonyl)aminopyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride
Treatment of cytomegalovirus disease in patients with impaired cell mediated immunity
Maribavir
Treatment of adenosine deaminase-deficient-severe combined immunodeficiency
Autologous CD34+ cells transduced with a lentiviral vector containing the human ADA gene
Treatment of retinitis pigmentosa
Recombinant human nerve growth factor
April 2013
Treatment of follicular thyroid cancer
Lenvatinib
Treatment of glioma
4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoline-6-carboxamide monohydrate
Treatment of papillary thyroid cancer
Lenvatinib
Treatment of Duchenne muscular dystrophy
R,S-O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic acid amidoxime dihydrochloride
Treatment of idiopathic pulmonary fibrosis
Nintedanib
Treatment of Niemann-Pick disease, type C
2-hydroxypropyl-β-cyclodextrin
Treatment of chronic lymphocytic leukaemia/small lymphocytic lymphoma
(S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
March 2013
Treatment of neuronal ceroid lipofuscinosis type 2
Recombinant human tripeptidyl-peptidase 1
Treatment of Stargardt’s disease
Ramiprilat
Treatment of Churg-Strauss Syndrome
Mepolizumab
Treatment of mantle cell lymphoma
1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H- pyrazolo [3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one
Treatment of congenital alpha-1 antitrypsin deficiency
Cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-Lglutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl] acetate salt
Prevention of graft rejection following solid organ transplantation
Murine IgM monoclonal antibody binding to alpha beta T-cell receptor
Treatment of sickle cell disease
Poloxamer 188
Treatment of chronic non-infectious uveitis
Gevokizumab
Treatment of Niemann-Pick disease, type C
Recombinant human heat shock protein 70
Treatment of hepatocellular carcinoma
4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoline-6-carboxamide monohydrate
Treatment of systemic sclerosis
2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indan-2-carboxylic acid
February 2013
Treatment of achromatopsia caused by mutations in the CNGB3 gene
Recombinant adeno-associated viral vector containing the human CNGB3 gene
Treatment of amyloid light-chain amyloidosis
Humanised IgG1 kappa antibody against serum amyloid A and AL amyloid
Treatment of moderate and severe traumatic brain injury
Progesterone
Treatment of high altitude pulmonary oedema
Cyclo-Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-Ala-Lys-Pro-Trp-Tyr-Cys
Treatment of chronic thromboembolic pulmonary hypertension
Treprostinil sodium
Treatment of systemic sclerosis
Terguride
Treatment of Duchenne muscular dystrophy
Humanised monoclonal antibody against myostatin
Treatment of acute myeloid leukaemia
L-asparaginase encapsulated in erythrocytes
January 2013
Treatment of follicular lymphoma
Lenalidomide
Treatment of familial adenomatous polyposis
Eflornithine in combination with sulindac
Treatment of growth hormone deficiency
Recombinant modified human growth hormone
Treatment of 5q spinal muscular atrophy
Allogeneic motor neuron progenitor cells derived from human embryonic stem cells
Treatment of Wilson’s disease
Choline tetrathiomolybdate
Treatment of pancreatic cancer
Recombinant human monoclonal antibody of the IgG1 kappa class against prostate stem cell antigen
Treatment of beta-thalassaemia intermedia and major
Autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human betaA-T87Q-globin gene
Treatment of ovarian cancer
Chimeric monoclonal antibody against claudin 6
Treatment of glioma
1,2:5,6-Dianhydrogalactitol
Treatment of achondroplasia
Modified recombinant human C-type natriuretic peptide
Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome)
Adeno-associated viral vector serotype 9 containing the human N-acetylglucosaminidase alpha gene
Treatment of systemic sclerosis
Terguride
Treatment of retinitis pigmentosa
Encapsulated human retinal pigment epithelial cell line transfected with plasmid vector expressing human ciliary neurotrophic factor